Bimekizumab Under Review for Moderate to Severe Hidradenitis Suppurativa

The FDA has accepted for review the sBLA for bimekizumab-bkzx for the treatment of adults with moderate to severe hidradenitis suppurativa.

Related Keywords

Emmanuel Caeymaex ,Immunology Solutions ,Drug Administration ,Biologics License Application ,Hidradenitis Suppurativa Clinical Response ,Executive Vice President ,